Literature DB >> 18354492

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.

T L Lasho, A Tefferi, J D Hood, S Verstovsek, D G Gilliland, A Pardanani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18354492     DOI： 10.1038/leu.2008.56

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  37 in total

1.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.

Authors:  Jason D Merker; Carol D Jones; Stephen T Oh; Iris Schrijver; Jason Gotlib; James L Zehnder
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

3.  JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.

Authors:  Fan Liu; Xinyang Zhao; Fabiana Perna; Lan Wang; Priya Koppikar; Omar Abdel-Wahab; Michael W Harr; Ross L Levine; Hao Xu; Ayalew Tefferi; Anthony Deblasio; Megan Hatlen; Silvia Menendez; Stephen D Nimer
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

4.  TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Authors:  Vijay Ramakrishnan; Teresa Kimlinger; Jessica Haug; Michael Timm; Linda Wellik; Timothy Halling; Animesh Pardanani; Ayalew Tefferi; Sundararasan Vincent Rajkumar; Shaji Kumar
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

5.  Cooperative epigenetic modulation by cancer amplicon genes.

Authors:  Lixin Rui; N C Tolga Emre; Michael J Kruhlak; Hye-Jung Chung; Christian Steidl; Graham Slack; George W Wright; Georg Lenz; Vu N Ngo; Arthur L Shaffer; Weihong Xu; Hong Zhao; Yandan Yang; Laurence Lamy; R Eric Davis; Wenming Xiao; John Powell; David Maloney; Craig J Thomas; Peter Möller; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Kerry Savage; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Dennis D Weisenburger; Wing C Chan; Randy D Gascoyne; David Levens; Louis M Staudt
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

6.  Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Authors:  Valerie Ugo; Sylvie Tondeur; Marie-Laurence Menot; Nadine Bonnin; Gerald Le Gac; Carole Tonetti; Veronique Mansat-De Mas; Lydie Lecucq; Jean-Jacques Kiladjian; Christine Chomienne; Christine Dosquet; Nathalie Parquet; Luc Darnige; Marc Porneuf; Martine Escoffre-Barbe; Stephane Giraudier; Eric Delabesse; Bruno Cassinat
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

Review 7.  Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Authors:  Neha Bhagwat; Ross L Levine; Priya Koppikar
Journal:  Int J Hematol       Date:  2013-05-14       Impact factor: 2.490

Review 8.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

9.  Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells.

Authors:  Zhaohui Ye; Cyndi F Liu; Lucie Lanikova; Sarah N Dowey; Chaoxia He; Xiaosong Huang; Robert A Brodsky; Jerry L Spivak; Josef T Prchal; Linzhao Cheng
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

10.  JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?

Authors:  Nicole Kucine; Ross L Levine
Journal:  Ther Adv Hematol       Date:  2011-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.